Table 3 Recent combination checkpoint inhibitor study results in melanoma

[42]

[43]

III

No

Ipilimumab

19.0

2.9 months

Nivolumab

43.7

6.9 months

Nivolumab + ipilimumab

57.6

11.5 months

[44]

III

No

Nivolumab + ipilimumab

52–61

8.5 months (BRAF mutant)

Not reached (BRAF wildtype)

Ipilimumab

11

2.7 months (BRAF mutant)

4.4 months (BRAF wildtype)

[46]

II

No

Pembrolizumab + ipilimumab

57

70 % at 6 months